Clinical trial · Observational
Standard of Care Lifestyle Support for Stage III NSCLC Patients
Improving Standard of Care Lifestyle Support for Stage III NSCLC Cancer Patients
NCT05287971CI-TRIAL-00069349PERCUSSIONwithdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Never started
Summary
Brief summary (as posted)
Offering an early-initiated supportive care program to stage III NSCLC patients to prevent deterioration of performance status and increase compliance of patients that complete chemoradiation as well as the patients receiving 12 months of durvalumab.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lifestyle advice | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Compliance
- timeFrame
- 12 months
- description
- Compliance to CCRT and durvalumab treatment
Secondary outcomes (10)
- measure
- Percentage adhering advice
- timeFrame
- 12 months
- description
- Improving standard of care lifestyle support by measuring % patients successfully adhering to the dietary, exercise, smoking advice
- measure
- Perctenage use of watch
- timeFrame
- 12 months
- description
- Improving standard of care lifestyle support by measuring % use of the watch (and app)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathological diagnosis of adequately staged (according to standard practice using chest-CT, FDG-PET, brain imaging MRI/CT) NSCLC * Participant is willing and able to give informed consent for participation in the trial * Aged 18 years or above * Scheduled to receive one of the following two therapeutic strategies: * Concurrent chemotherapy and radiotherapy with photons (60 Gy in 30 fractions of 2 Gy) followed by durvalumab in patients with stage III NSCLC * Concurrent chemotherapy and radiotherapy with protons (60 Gy in 30 fractions of 2 Gy) followed by durvalumab in patients with stage III NSCLC * Able and willing to comply with all trial requirements Exclusion Criteria: * Mixed non-small cell lung cancer with other histology such as small cell lung cancer * Not able to comply with the study protocol * Less than 18 years old * Pregnancy or not able to comply with adequate contraception in women with child baring potential * Previous radiotherapy to the chest for benign or malignant conditions, including radiation for breast cancer * Previous malignancy treated with chemotherapy, immune therapy or radiotherapy (irrespective of when this happened) * Previous malignancies treated with surgery only are allowed if 2 years or more before inclusion in the present study
References
Publications (0)
Data not yet available
No reference posted for this study.